Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12605000292673
ACTRN12605000292673
Recruiting
Phase 4

A Preliminary Crossover Study of the Pharmacokinetics and Clinical Efficacy of Hydromorphone Nasal Analgesia Spray versus Intravenous Hydromorphone for Postoperative Pain

Stephen Lim0 sites30 target enrollmentSeptember 5, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAnalgesia for Postoperative PainAlternative and Complementary Medicine - Pain management

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Analgesia for Postoperative Pain
Sponsor
Stephen Lim
Enrollment
30
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 5, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Stephen Lim

Eligibility Criteria

Inclusion Criteria

  • •ASA 1 or 2\. Major Gynaecological Surgery involving skin or mucosal incision (e.g. laparotomy, total abdominal hysterectomy, vaginal hysterectomy \+/\- anterior/posterior repair).Decision to use patient controlled intravenous analgesia (PCIA) in the postoperative period.

Exclusion Criteria

  • •Nasal pathology.Allergy to shellfish (chitosan a natural constituent of mollusc seashell is added to the hydromorphone mixture to aid in prolonging mucosal absorption).Intolerance to opioids.Decision to use epidural analgesia postoperatively.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.Blooddiseaseleukemia/lymophoma10047954
NL-OMON35094Calistoga Pharmaceuticals Inc.15
Completed
Phase 1
Pharmacokinetic drug-drug interaction study between oral 300 mg netupitant/0.50 mg palonosetron fixed dose combination (Akynzeo®) and oral dexamethasone to evaluate the duration of the CYP3A4 inhibition in healthy subjectsInhibitory effect on CYP3A4Not Applicable
ISRCTN93845260Helsinn Healthcare SA24
Active, not recruiting
Phase 1
This study will test an experimental drug named GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) for the possible treatment of human immunodeficiency virus (HIV) infection in children and adolescents. The purpose of this study is to determine the concentration of GS-9883 in your child's body, and confirm the safety, tolerability and dose of GS-9883/F/TAF in HIV-1 infected adolescents (12 to < 18 years of age) and children (6 to <12 years of age).
EUCTR2016-002345-39-Outside-EU/EEAGilead Sciences, Inc.
Active, not recruiting
Not Applicable
A clinical research study to examine the pharmacokinetics, safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 infected adolescents.
EUCTR2015-000313-40-Outside-EU/EEAGilead Sciences, Inc.50
Active, not recruiting
Phase 1
A clinical study looking at the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected adolescents who have never previously been treated and in children who are currently receiving treatment.
EUCTR2013-002780-26-Outside-EU/EEAGilead Sciences, Inc.100